G Mikan - Bright Health President, Chief Executive Officer, Director
| BHGDelisted Stock | USD 12.29 0.39 3.08% |
CEO
G Mikan is President, Chief Executive Officer, Director of Bright Health Group since 2020.
| Age | 49 |
| Tenure | 4 years |
| Phone | 612 238 1321 |
| Web | https://www.brighthealthgroup.com |
Bright Health Management Efficiency
The company has Return on Asset of (0.0701) % which means that on every $100 spent on assets, it lost $0.0701. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.1855) %, meaning that it generated no profit with money invested by stockholders. Bright Health's management efficiency ratios could be used to measure how well Bright Health manages its routine affairs as well as how well it operates its assets and liabilities.Bright Health Group has 303.95 M in debt with debt to equity (D/E) ratio of 0.02, which may show that the company is not taking advantage of profits from borrowing. Bright Health Group has a current ratio of 0.85, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Bright to invest in growth at high rates of return.
Similar Executives
| Found 10 records | CEO Age | ||
| Andrew Witty | UnitedHealth Group Incorporated | 55 | |
| David Wichmann | UnitedHealth Group Incorporated | 56 | |
| Larry Merlo | CVS Health Corp | 63 | |
| Rich Fisher | Centene Corp | N/A | |
| Dirk McMahon | UnitedHealth Group Incorporated | 64 | |
| Karen Lynch | CVS Health Corp | 61 | |
| Gail Boudreaux | Elevance Health | 63 | |
| David Cordani | Cigna Corp | 59 | |
| Timothy Wentworth | Cigna Corp | 59 | |
| Joseph Zubretsky | Molina Healthcare | 67 | |
Management Performance
| Return On Equity | -1.19 | |||
| Return On Asset | -0.0701 |
Bright Health Group Leadership Team
Elected by the shareholders, the Bright Health's board of directors comprises two types of representatives: Bright Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bright. The board's role is to monitor Bright Health's management team and ensure that shareholders' interests are well served. Bright Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bright Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Simeon Schindelman, Chief Executive Officer of Bright HealthCare | ||
| Matthew Manders, Independent Director | ||
| Jeffrey Folick, Independent Director | ||
| Megan North, President NeueSolutions | ||
| Stephen Kraus, Independent Director | ||
| Jeffrey Scherman, Chief Officer | ||
| Mohamad Makhzoumi, Independent Director | ||
| Jay Matushak, Chief Officer | ||
| Tomas Valdivia, Co-Founder, Chief Health and Equity Officer | ||
| Joaquin MD, President Care | ||
| Tomas Orozco, Executive Care | ||
| Adair Newhall, Independent Director | ||
| Catherine Smith, Chief Financial and Administrative Officer | ||
| Jeffrey Immelt, Independent Director | ||
| Brett Erhardt, Chief Officer | ||
| Kedrick Adkins, Independent Director | ||
| Linda Gooden, Independent Director | ||
| G Mikan, President, Chief Executive Officer, Director | ||
| Tomas MS, CoFounder Officer | ||
| Keith Nelsen, General Counsel, Corporate Secretary | ||
| George III, CEO Chairman | ||
| Jeff Craig, General Counsel, Corporate Secretary | ||
| Jeffrey Cook, Chief Officer | ||
| Sam Srivastava, Chief Executive Officer of NeueHealth | ||
| Stephen CFA, Director Relations | ||
| Stacy Conti, Chief Officer | ||
| Andrew Slavitt, Independent Director | ||
| Manuel Kadre, Independent Director | ||
| Bob Sheehy, Executive Chairman, Co-Founder | ||
| Mike Mikan, President, Chief Executive Officer | ||
| Naomi Allen, Independent Director | ||
| Robert Sheehy, Executive Chairman of the Board |
Bright Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bright Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.19 | |||
| Return On Asset | -0.0701 | |||
| Profit Margin | (0.58) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 1.25 B | |||
| Shares Outstanding | 7.98 M | |||
| Shares Owned By Insiders | 4.93 % | |||
| Shares Owned By Institutions | 65.02 % | |||
| Number Of Shares Shorted | 104.17 K | |||
| Price To Book | 0.95 X |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Bright Stock
If you are still planning to invest in Bright Health Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bright Health's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |